Výsledky vyhledávání - "Robert D, Gross"

A Prospective, Randomized Trial of Povidone-Iodine 0.6% and Dexamethasone 0.1% Ophthalmic Suspension for Acute Bacterial Conjunctivitis

Autor: Christopher N. Ta, Robert D. Gross, Yuemei Wang, Sushanta Mallick, Bruce Segal, Michael B. Raizman, Sunir Joshi

Publikováno v: American journal of ophthalmology. 215

To evaluate the efficacy and safety of a topical ophthalmic suspension combination of povidone-iodine 0.6% (PVP-I) and dexamethasone 0.1% (DEX) for infectious and inflammatory components of bacterial conjunctivitis.Randomized, double-masked, multicen

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::913260ea69abf00f0a80f3acb5389888
https://pubmed.ncbi.nlm.nih.gov/32826036

Zobrazit plný text záznamu

Betaxolol hydrochloride ophthalmic suspension 0.25% and timolol gel-forming solution 0.25% and 0.5% in pediatric glaucoma: A randomized clinical trial

Autor: Devindra Sood, Alan L. Robin, Robert D. Gross, Parthasarathy Sathyan, Jaime E. Dickerson, Peter A. Netland, Sally A. Scheib, Jess T. Whitson, David A. Plager, Lingam Vijaya, Subbiah. R. Krishnadas, Haydn Scott

Publikováno v: Journal of American Association for Pediatric Ophthalmology and Strabismus. 13:384-390

Purpose To describe the safety profile and clinical response on elevated intraocular pressure (IOP) of betaxolol hydrochloride ophthalmic suspension 0.25% (betaxolol) and timolol maleate ophthalmic gel-forming solution (TGFS) (0.25% and 0.5%), in sub

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03f22611f324013ac15ea9fd28029b6e
https://doi.org/10.1016/j.jaapos.2009.04.017

Zobrazit plný text záznamu

Efficacy of olopatadine ophthalmic solution 0.2% in reducing signs and symptoms of allergic conjunctivitis

Autor: Stella M. Robertson, Robert D. Gross, Mark B. Abelson, Michael R. Edwards, Terri Pasquine, Paul J Gomes

Publikováno v: Allergy and asthma proceedings. 28(4)

Olopatadine hydrochloride ophthalmic solution 0.2% (Pataday, Alcon) is a new formulation of olopatadine hydrochloride ophthalmic solution, the first topical ocular antiallergic agent indicated for once-daily dosing. The aim of this study was to evalu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d5fb37bf4e129f29bce6d3a012a9286
https://pubmed.ncbi.nlm.nih.gov/17883910

Zobrazit plný text záznamu

Safety and tolerability of olopatadine 0.2% in children and adolescents

Autor: Michael R. Edwards, Stella M. Robertson, Steven J. Lichtenstein, Terry A. Pasquine, Robert D. Gross, David T. Wells

Publikováno v: Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics. 23(4)

The aim of this study was to evaluate the safety of olopatadine hydrochloride ophthalmic solution 0.2% in children and adolescents 3-17 years of age.In this 6-week, randomized, double-masked safety evaluation, eligible subjects with asymptomatic eyes

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b56dfc2f3ecbab43fe01e49dc3f5b70
https://pubmed.ncbi.nlm.nih.gov/17803435

Zobrazit plný text záznamu

Randomized, placebo-controlled evaluation of Cerumenex and Murine earwax removal products

Autor: Peter J. Conroy, G. Michael Wall, Peter S. Roland, Rekha Garadi, Gail Hogg, Debbie Eaton, Laura LaFontaine, Susan L. Potts, Robert D. Gross

Publikováno v: Archives of otolaryngology--headneck surgery. 130(10)

Objective To evaluate the efficacy of 2 ceruminolytic products, Cerumenex Eardrops (Purdue Frederick Company, Norwalk, Conn) and Murine Ear Drops (Abbott Laboratories, Abbott Park, Ill), in subjects with partial or complete occlusion of the ear canal

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30a867963d33e08e94e5c4b7b125d62d
https://pubmed.ncbi.nlm.nih.gov/15492164

Zobrazit plný text záznamu

Clinical efficacy of olopatadine hydrochloride ophthalmic solution 0.2% compared with placebo in patients with allergic conjunctivitis or rhinoconjunctivitis: a randomized, double-masked environmental study

Autor: David T. Wells, Mark B. Abelson, Cullen T. Vogelson, Stella M. Robertson, F. Darell Turner, Terri Pasquine, Paul J Gomes, M.V. W. Bergamini, Robert D. Gross

Publikováno v: Clinical therapeutics. 26(8)

Previous studies have suggested that olopatadine hydrochloride ophthalmic solution 0.2% administered once daily is effective for up to 24 hours after instillation and is well tolerated in adults and children agedor =3 years.The goal of this study was

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eee6a93816ed0a39e8e9ff7e675f4e24
https://pubmed.ncbi.nlm.nih.gov/15476905

Zobrazit plný text záznamu

Preclinical and clinical antiallergic effect of olopatadine 0.2% solution 24 hours after topical ocular administration

Autor: Cullen T, Vogelson, Mark B, Abelson, Terri, Pasquine, Donna M, Stephens, Daniel A, Gamache, Robert D, Gross, Stella M, Robertson, John M, Yanni

Publikováno v: Allergy and asthma proceedings. 25(1)

Pharmacologic studies examined the potential of a solution containing olopatadine to maintain and extend antiallergic efficacy after single topical ocular drop administration over 24 hours. Results of these preclinical experiments conducted in guinea

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::7b09412b9dc1c68ab2acce795b4d7e90
https://pubmed.ncbi.nlm.nih.gov/15055565

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání